Theravance Biopharma Inc (NASDAQ:TBPH) received a $55.00 price target from analysts at Cantor Fitzgerald in a report released on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 103.48% from the company’s current price.

Several other equities research analysts also recently commented on TBPH. Needham & Company LLC upped their target price on shares of Theravance Biopharma from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. Leerink Swann set a $47.00 target price on shares of Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, May 10th. ValuEngine raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Four analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $41.13.

Shares of Theravance Biopharma (NASDAQ TBPH) traded up 1.20% during midday trading on Wednesday, hitting $27.03. 188,122 shares of the company’s stock were exchanged. The firm’s market cap is $1.45 billion. Theravance Biopharma has a 52 week low of $23.15 and a 52 week high of $43.44. The company has a 50-day moving average of $34.62 and a 200-day moving average of $35.42.

WARNING: “Cantor Fitzgerald Analysts Give Theravance Biopharma Inc (TBPH) a $55.00 Price Target” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/16/cantor-fitzgerald-analysts-give-theravance-biopharma-inc-tbph-a-55-00-price-target.html.

In related news, Director Henrietta Fore purchased 6,000 shares of Theravance Biopharma stock in a transaction dated Friday, August 11th. The stock was bought at an average price of $23.99 per share, for a total transaction of $143,940.00. Following the completion of the acquisition, the director now directly owns 24,000 shares of the company’s stock, valued at $575,760. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Rick E. Winningham purchased 10,000 shares of Theravance Biopharma stock in a transaction dated Friday, August 11th. The stock was bought at an average price of $24.50 per share, with a total value of $245,000.00. Following the acquisition, the chief executive officer now directly owns 866,377 shares of the company’s stock, valued at $21,226,236.50. The disclosure for this purchase can be found here. 6.10% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Woodford Investment Management Ltd boosted its position in Theravance Biopharma by 1.9% in the first quarter. Woodford Investment Management Ltd now owns 10,705,108 shares of the biopharmaceutical company’s stock valued at $393,948,000 after buying an additional 197,500 shares during the period. BlackRock Inc. boosted its position in Theravance Biopharma by 3.6% in the second quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock valued at $144,972,000 after buying an additional 126,393 shares during the period. Vanguard Group Inc. boosted its position in Theravance Biopharma by 3.8% in the second quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock valued at $127,379,000 after buying an additional 116,981 shares during the period. State Street Corp boosted its position in Theravance Biopharma by 2.2% in the second quarter. State Street Corp now owns 889,682 shares of the biopharmaceutical company’s stock valued at $35,443,000 after buying an additional 19,428 shares during the period. Finally, MARSHALL WACE ASIA Ltd bought a new position in Theravance Biopharma during the first quarter valued at $21,862,000. Institutional investors own 82.77% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.